Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma (NCT05032820), a na phase 2 study. The primary outcome is Efficacy of BCMA CAR-T Cell Therapy.

2. Clinical Question

The clinical question is about response upgrading in a selected treatment setting, rather than a comparison of bb2121 against another assigned treatment. Participants had already undergone autologous HCT and lenalidomide maintenance, and entered the study because their disease response was described as suboptimal. The result would therefore characterize the response status recorded after therapy in this study population; it would not, by itself, estimate the difference between treatment strategies.

The primary endpoint is framed as a threshold at six months: achieving complete response or stringent complete response. It does not represent every possible change in disease status, and the registry also lists a secondary outcome concerning upgrade in best disease response. The relationship between those outcomes, including how response assessments were adjudicated and how missing assessments were handled, is not reported in the registry record.

3. Trial Design

This is a Phase II, multicenter, single-group trial with an enrollment of 40. Its registry status is completed. The recorded study start is 2022-01-05 and the primary completion date is 2024-08-22. Medical College of Wisconsin is listed as the sponsor. The title identifies the study as an investigation of upfront CAR T-cell therapy to upgrade response in multiple myeloma, while the official title describes anti-BCMA CAR T-cell therapy for patients with suboptimal response after autologous HCT and lenalidomide maintenance.

The treatment group is named Lenalidomide and bb2121. The listed interventions include lenalidomide, bb2121, cyclophosphamide, fludarabine, and leukapheresis. The arm description says that patients complete apheresis and proceed to lymphodepleting chemotherapy with cyclophosphamide 300mg/m^2 and fludarabine 30mg/m^2 for 3 consecutive days, followed by BCMA CAR T-cell infusion at a target dose of 450 x10^6 cells. It also describes maintenance lenalidomide starting at 5mg a day for 21 days of; the remainder of that schedule is not reported in the registry record.

Because the design is single group, participants are not allocated between a treatment group and a concurrent control group. The listed allocation is NA, the model is single group, and masking is none. These design features mean the study can describe outcomes among treated participants, but does not produce a randomized treatment contrast. Changes in response after treatment cannot be separated from other influences using a randomized comparison within this trial.

The registry lists 18 outcome measures and one analysis. This count does not establish which analytic methods were used or how outcomes were prioritized beyond the designation of the primary outcome. Details such as the statistical analysis plan, analysis populations, handling of missing assessments, and any interim analyses are not reported in the registry record. No sample-size justification is reported in the registry record.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Before assignment: There was a Safety Run-in that included the first three participants enrolled on the study with staggered enrollment to assess for excess early toxicity. These data were reviewed and enrollment was approved in the Continuing Enrollment Phase which began on October 14, 2022.

Overall Study

Reasons for not completing this period:

Analysis population for the primary outcome, as defined in the registry: Patients who received BCMA CAR T-Cell Therapy

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

Population: Enrolled Participants

6. Primary Endpoint

The registry lists the primary outcome as Efficacy of BCMA CAR-T Cell Therapy, measured over 6 months.

The primary endpoint is the count of participants achieving a complete response or stringent complete response at the six-month time point after BCMA CAR T-cell therapy. The registry defines the endpoint for patients with multiple myeloma whose response after autologous HCT and lenalidomide maintenance was suboptimal. The outcome unit is participants, and the population is described as patients who received BCMA CAR T-cell therapy.

This endpoint focuses on a clinically interpretable response category at a specified follow-up point. In general, a fixed-time response measure asks whether each participant meets the defined response criterion by that assessment time. The count can describe how many participants were recorded as meeting the criterion, but interpretation also depends on knowing how many participants were assessed and how missing assessments were treated. Those details, as well as the observed endpoint count, are not reported in the registry record.

The registry also lists a secondary outcome for the proportion of patients achieving an upgrade in response based on their best disease response. That is not identical to the primary endpoint: the primary endpoint names complete response or stringent complete response at six months, while the secondary outcome refers to an upgrade based on best response. The registry record does not report the response assessment criteria or explain how the two measures were operationalized. Without a reported result and denominator, the primary endpoint cannot be used to quantify response frequency or precision.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

The registry describes the primary outcome as a count of participants, with a binary response definition: a participant either achieved complete response or stringent complete response at the six-month time point, or did not meet that definition. This describes the outcome type, not the statistical procedure used to analyze it. The actual result and analysis method for the primary endpoint are not reported in the registry record.

What a count can tell you

A count records the number of participants meeting an outcome definition. To interpret a count as a response frequency, the denominator is also needed: it should be clear how many participants were eligible for assessment and how many had an assessment recorded. For this study, the registry describes the population as patients who received BCMA CAR T-cell therapy, but the number treated and the number assessed at six months are not reported in the registry record. Enrollment is not necessarily the same as the endpoint denominator.

In general, an estimated proportion expresses the count meeting a binary outcome relative to a defined denominator. A confidence interval describes statistical uncertainty around an estimate under the assumptions of the method used. It is not a guarantee that the true value lies within the interval, nor does it account automatically for design limitations, missing assessments, or bias. No proportion or confidence interval for the primary endpoint is reported in the registry record, so the precision of that result cannot be evaluated.

What a single-group design means

The registry identifies this as a single-group study with no masking and allocation listed as NA. In general, a single-group analysis can describe the outcomes observed among participants receiving the study treatment. It cannot provide a randomized estimate of the difference between that treatment and a comparator. Even if a response count were available, interpreting it as an effect caused by the treatment would require assumptions that this design cannot verify through a concurrent randomized control group.

A comparison with an external benchmark would require a stated benchmark and an analysis designed for that comparison. Neither a benchmark nor such a comparison is reported in the registry record. The clinical question and result should therefore be read as descriptive of the study group, rather than as evidence from a head-to-head trial.

How to read time-to-event outcomes

The listed secondary outcomes include cumulative incidence of disease progression and Kaplan-Meier progression-free survival. In general, time-to-event methods use both whether an event occurred and when it occurred. Kaplan-Meier methods can account for participants whose follow-up ends before an event is observed by treating their data as censored at the last known follow-up, subject to assumptions about censoring. Cumulative-incidence methods are used when events that prevent the event of interest need to be distinguished. The specific event definitions, censoring rules, competing-event approach, estimates, and confidence intervals for this trial are not reported in the registry record.

These methods cannot be inferred simply from the outcome names. The registry lists outcome titles, but does not report the statistical analysis plan. It is therefore not possible to establish whether particular estimators, tests, covariate adjustments, or sensitivity analyses were used.

What statistical significance and power would mean

In general, a significance test evaluates how compatible the data are with a specified null hypothesis under the test’s assumptions. A p-value does not measure the probability that a treatment works, and it does not show the size or clinical importance of an effect. A confidence interval is usually more informative about the range of estimates compatible with the data, while still depending on the design and assumptions. No primary-endpoint p-value or confidence interval is reported in the registry record.

The registry includes sample-size planning illustrations described as based on an observed effect, with a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation. Those assumptions describe an illustration, not this trial’s single-group design or its own reported analysis. The illustrations are not observed power and should not be interpreted as evidence that the trial had a particular probability of detecting an effect. No trial-specific sample-size justification is reported in the registry record.

General statistical concepts explain how results might be analyzed, but they do not establish which methods were used. For this study, the reported design is single group and the primary measure is a participant count; further details of the analysis are not reported in the registry record.

10. Multiplicity, Missing Data and Analysis Populations

The registry lists 18 outcome measures, including the primary six-month response endpoint and secondary measures covering response upgrade, disease progression, progression-free survival, non-relapse mortality, and adverse events. When a study examines multiple outcomes, the chance of at least one apparently notable result can increase if many tests are performed without a prespecified strategy. In general, multiplicity can be addressed by prioritizing a primary outcome, adjusting inference, or treating secondary analyses as exploratory. The registry record does not report whether any multiplicity adjustment or hierarchical testing strategy was planned or used.

The record identifies the primary outcome, but does not provide the analysis plan, outcome-level testing procedures, or inferential results. It is not possible to determine from the registry information whether the secondary outcomes were confirmatory, descriptive, or exploratory. The number of listed outcomes alone does not reveal how multiplicity was handled.

Missing-data procedures are also not reported in the registry record. This matters for the six-month response endpoint because the number enrolled, the number treated, and the number with an assessed response may differ. The record does not state how unavailable assessments were classified, whether participants who discontinued treatment remained in an analysis population, or whether any imputation or sensitivity analysis was conducted.

The primary population is described as patients who received BCMA CAR T-cell therapy, but a complete definition of analysis populations is not reported in the registry record. Details on exclusions, protocol deviations, and handling of participants with incomplete follow-up are also not reported. These gaps limit assessment of whether the reported analysis, if available, would represent all enrolled participants or a selected subset.

11. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Deaths

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: cytokine release syndrome (12.5%), pneumonia (5.0%), bile duct stone (2.5%), pyelonephritis (2.5%), transient ischaemic attack (2.5%).

The registry safety summary lists 40 participants at risk for serious adverse events and 9 affected. For other adverse events, it lists 40 at risk and 38 affected. It also records 0 deaths. These are descriptive counts; they are not comparative estimates against a control group, because this is a single-group trial.

The serious adverse-event terms listed include Cytokine Release Syndrome at 12.5%, Pneumonia at 5.0%, Bile duct stone at 2.5%, Pyelonephritis at 2.5%, and Transient ischaemic attack at 2.5%. These percentages are reproduced as registry entries. The record does not report the event counts behind each percentage, the time period used for each term, or whether participants could contribute more than one event. They should not be converted into participant counts without that information.

In general, an adverse event is not automatically an event caused by treatment. Causal attribution requires information about assessment and reporting, which is not reported in the registry record. The summary also does not provide the duration of risk observation, event grades, resolution status, or a comparison of risk between treatment strategies. The figures should therefore be read as the registry’s safety summary, not as proof of causation or as a complete account of safety.

12. What the Result Does, and Does Not, Mean

The study is designed to describe whether people with multiple myeloma and a suboptimal response after autologous HCT and lenalidomide maintenance achieved complete response or stringent complete response at six months after BCMA CAR T-cell therapy. The registry also lists broader disease, survival, and safety outcomes. That framing makes the trial relevant to a specific clinical setting and response question.

However, the registry record does not report the observed primary response count, the assessed denominator, or an uncertainty interval. As a result, the primary efficacy outcome cannot be quantified from this record. The completed status and enrollment of 40 do not substitute for an outcome estimate. They indicate trial status and planned or recorded enrollment, not the number meeting the endpoint.

Even with a complete outcome count, the single-group design would support description of results among treated participants, not a randomized comparison. It could not by itself establish how outcomes would differ under another treatment strategy. General differences in patient characteristics, disease course, and care can affect outcomes in an uncontrolled study, and the design does not provide a concurrent control to balance those influences.

The adverse-event summary reports counts and selected serious-event terms, but does not establish that events were caused by therapy. It also does not provide the detail needed to compare safety across treatments. Likewise, outcome titles for progression, response upgrade, non-relapse mortality, and neurotoxicity do not establish their results or the methods used to analyze them.

The most defensible interpretation is therefore limited to the registry’s stated design, intervention, endpoint definitions, enrollment, and posted safety summaries. Claims about the size or precision of a response effect, comparative benefit, or treatment-related risk are not supported by the results reported in the registry record.

13. Why This Trial Matters Statistically

This study addresses a clearly defined treatment setting: multiple myeloma after autologous HCT and lenalidomide maintenance when the recorded disease response is suboptimal. The primary endpoint focuses on whether a high-level response category is present at six months following BCMA CAR T-cell therapy. Defining the population and time point matters statistically because estimates are interpretable only in relation to who was assessed and when.

The design also highlights the distinction between an outcome description and a comparative treatment effect. A single-group trial can document outcomes in participants who received the intervention, but it cannot use randomization to separate treatment effects from other influences. That makes clear reporting of eligibility, treated population, follow-up, outcome assessment, and missing data particularly important.

The registry identifies a range of additional outcomes spanning progression, response, survival, mortality, and adverse events. Such breadth can help describe different aspects of a study, but it also makes the analysis plan important: readers need to know which outcomes were prioritized and how multiple analyses were interpreted. Those details are not reported in the registry record.

The record also illustrates why registry design information and result information must be considered separately. Trial status, enrollment, endpoint definitions, and safety summaries are useful, but they cannot replace a reported endpoint estimate with its denominator and uncertainty. For this trial, the lack of a reported primary outcome result prevents assessment of response frequency and precision from the registry record.

14. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The central limitation for interpreting efficacy is that the registry record does not report the primary endpoint result. Neither the number achieving complete response or stringent complete response nor the denominator assessed at six months is reported. Without those values, no response frequency or precision estimate can be described.

The study has a single-group design, with allocation listed as NA and masking as none. It does not include a randomized control group for a like-for-like treatment comparison. Consequently, the design does not directly estimate a treatment difference, and any outcome description would apply to the treated study population rather than establish what would have happened under an alternative strategy.

The registry describes an enrollment of 40 and defines the primary population as patients who received BCMA CAR T-cell therapy, but the number treated and the number with evaluable follow-up are not reported in the registry record. The rules for response assessment, analysis populations, missing data, and incomplete follow-up are also not reported. These omissions impede interpretation of the endpoint denominator and potential selection arising from incomplete outcome ascertainment.

Although the record lists 18 outcome measures and one analysis, it does not report the statistical analysis plan, methods for controlling multiplicity, or outcome-specific inferential results. Details for time-to-event analyses, including censoring and competing-event methods, are not reported in the registry record. Nor is a trial-specific sample-size justification reported.

The safety summary gives counts for participants affected by serious and other adverse events and lists selected serious-event terms, but does not report event timing, duration of observation, attribution, or severity grading in the registry record for this record. These limitations constrain interpretation of both efficacy and safety.

15. Related Tutorials

16. Related Statistical Calculators

17. Sources

• ClinicalTrials.gov: Upfront Chimeric Antigen Receptor T-Cell to Upgrade Response in Multiple Myeloma — NCT05032820.
• Registry record last updated 2026-05-19; status last verified 2026-05.
• Results first posted 2026-01-12.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

18. Record Summary

NCT05032820 is a completed Phase II multicenter, single-group trial sponsored by Medical College of Wisconsin. It enrolled 40 participants and studied bb2121 BCMA CAR T-cell therapy in multiple myeloma after suboptimal response following autologous HCT and lenalidomide maintenance. The recorded study start is 2022-01-05, and primary completion is dated 2024-08-22.

The primary endpoint is the count achieving complete response or stringent complete response at six months among patients who received BCMA CAR T-cell therapy. The registry record does not report that endpoint result, its denominator, or an uncertainty estimate. The safety summary lists 9 of 40 at risk as affected by serious adverse events, 38 of 40 as affected by other adverse events, and 0 deaths. Listed serious-event terms include Cytokine Release Syndrome, Pneumonia, Bile duct stone, Pyelonephritis, and Transient ischaemic attack, with registry percentages. No randomized comparator is included.